GlassScriptPhysician profile
Gary L Crump
NPI 1285709386
$175,691.43
in general payments reported to CMS, 2019-2025
37 companies · $3,626 in 2025
The $3,626 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $29K · 2021: $27K · 2022: $30K · 2023: $27K · 2024: $13K · 2025: $3,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $19K · Food and Beverage: $14K · Consulting Fee: $7,600 · Travel and Lodging: $3,314 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $19,350.00 |
| Food and Beverage | $13,511.59 |
| Consulting Fee | $7,600.00 |
| Travel and Lodging | $3,313.73 |
| Education | $193.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $71,233.80 | 2019-2023 | Krystexxa, Uplizna |
| Abbvie INC. | $31,194.60 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Novartis Pharmaceuticals Corporation | $24,693.86 | 2019-2025 | |
| Amgen INC. | $19,668.85 | 2019-2025 | Uplizna, Krystexxa, Enbrel |
| Ucb, INC. | $15,682.11 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $3,347.09 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Mallinckrodt Hospital Products INC. | $1,422.89 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $1,193.64 | 2021-2025 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $1,002.46 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $950.82 | 2019-2025 | Ofev, Cyltezo |
| Pfizer INC. | $800.17 | 2019-2025 | |
| Glaxosmithkline, LLC. | $527.00 | 2019-2025 | Benlysta, Nucala |
| Regeneron Healthcare Solutions, INC. | $518.11 | 2019-2020 | |
| Johnson & Johnson Health Care Systems INC. | $424.71 | 2019-2022 | |
| Lilly USA, LLC | $395.80 | 2019-2024 | Taltz |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $373.25 | 2022-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $262.81 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $252.69 | 2022-2025 | Strensiq |
| Radius Health, INC. | $225.93 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $180.09 | 2019-2025 | Actemra, Gazyva |
| Pacira Therapeutics, INC. | $163.69 | 2019-2021 | |
| Sandoz INC. | $162.97 | 2023-2025 | Hyrimoz |
| Celgene Corporation | $141.64 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $128.05 | 2023-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $123.26 | 2019 | |
| Organon LLC | $114.20 | 2023-2025 | Hadlima, Renflexis |
| Mallinckrodt Enterprises LLC | $95.80 | 2019 | |
| Sobi, INC | $95.75 | 2019-2025 | |
| Ultragenyx Pharmaceutical INC. | $61.25 | 2023 | |
| Genentech, INC. | $49.95 | 2021 | |
| Merck Sharp & Dohme LLC | $36.72 | 2019-2020 | |
| Antares Pharma, INC. | $36.30 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $32.55 | 2025 | Uptravi |
| Orthogenrx INC. | $32.03 | 2019 | |
| Fresenius Kabi USA, LLC | $28.98 | 2025 | Tyenne |
| Hikma Pharmaceuticals USA | $24.87 | 2019-2023 | Mitigare |
| Ferring Pharmaceuticals INC. | $12.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Crump listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.